Versea Ophthalmics Announces Novel Application of Biovance Product Portfolio in Retinal Procedures

Verséa Ophthalmics has announced that results from recent application of Biovance and Biovance 3L Ocular products in macular hole repair will be presented at the upcoming Retinal World Congress (RWC) being held from May 8-11, 2025 in Fort Lauderdale, FL.

The macular hole repair procedures were performed at Ophthalmics Consultants of Long Island by Deepika Malik, MD. The results of these early experience procedures will be presented as an ePoster video during RWC. In addition, Dr. Malik has been invited by the RWC Committee to participate in a panel discussion to be held on May 8  from 2:15 pm – 2:35 pm ET.

Biovance and Biovance 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix. Biovance 3L Ocular is decellularized and consists of three layers of amniotic basement membrane that supports treatment of various ocular conditions, both clinically and surgically. As a barrier membrane, Biovance 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries. Applications include corneal and conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix reconstruction, and other procedures, many of which are relevant to ophthalmology practices and their eye care professional teams.